PCV56 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150 MG FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY THAT HAVE MODERATE IMPAIRMENT OF RENAL FUNCTION
May 1, 2009, 00:00
10.1016/S1098-3015(10)73818-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)73818-3/fulltext
Title :
PCV56 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150 MG FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY THAT HAVE MODERATE IMPAIRMENT OF RENAL FUNCTION
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73818-3&doi=10.1016/S1098-3015(10)73818-3
First page :
Section Title :
Open access? :
No
Section Order :
287